AMRX

In the past six months, Amneal Pharmaceuticals' stock (AMRX) has trended upwards by 55.55%. Key events include strong fiscal Q2 2026 performance and increased full-year guidance reported on July 30, 2026, which surpassed analyst expectations and led to raised guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS. On September 18, 2026, the company received U.S. FDA approval and immediately launched its lanreotide injection, a generic referencing SOMATULINE® Depot, which caused the stock to surge 12.5% on September 21, 2026. The strategic acquisition of Kashiv BioSciences was also a key factor in its stock performance. Additionally, the company expanded its injectables portfolio with further FDA approvals, such as romidepsin injection solution in June 2026. Analyst coverage included Oppenheimer initiating an 'Outperform' rating with a $27 price target in September 2026, though Zacks Research cut the stock rating to 'Strong Sell' in October 2026.